Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai, has announced initiation of enrollment in a Phase I study of MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer malignancies.
Subscribe to our email newsletter
The open-label Phase I study is designed to assess the safety, tolerability and pharmacokinetics of MORAb-066 administered with weekly intravenous infusions.
Morphotek president and CEO Nicholas Nicolaides said, "New agents are needed for cancer treatment and our strategy of using collaborations with leading research institutions provides us opportunities to develop novel medicines that target disease-specific pathways."
A humanized monoclonal antibody, MORAb-066 targets tissue factor (TF), a protein whose role under normal conditions is to support blood coagulation.
In cancer, it has been shown that TF is a membrane-bound antigen expressed by tumor endothelial cells that is hypothesized to play a role in promoting tumor angiogenesis and growth.
Earlier, Janssen Biotech granted exclusive worldwide rights to develop and commercialize the antibody to Morphotek.